Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Charts for Quick CASH $$$ -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (7185)	4/9/1998 10:35:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 9262

[ GLIA ] >> Honorable mention to those from our old list...... GLIA, REGN and HYSQ<< There's news out today for GLIA...... prnewswire.com GLIA always seems to be slow to react to news. It has very little coverage, and many of the investors seem to be local to Cleveland and to obtain their news from the daily newspaper. I'm not encouraging anybody to run into news that is already out, but....... it may soon sink in that this is favorable labeling for 400K X approximately $400 per procedure, or a U.S. market of about $160 million. Investors will start to realize that there are only 7.4 million shares out, and that only 10% penetration of the U.S. market will be about $2/share of revenue. Add that (1) we're waiting for approval of reimbursement in key european countries, (2) the Alzheimer's program with Janssen (Johnson and Johnson) has recently been renewed (leads are in optimization), (3) the H3R antagonist program is not yet partnered but has already attracted the attention of at least one pharma, (4) Adcon-L sales in Europe are already ramping up, and (5) Adcon-T/N is coming along and addresses a market that is similar in size to that of Adcon-L, and it would seem that we're markedly undervalued. I don't usually set targets. There's probably some dilution coming, but.... given the labeling that FDA is allowing for this product and the data for resurgery that seems to have gone unchallenged.... I feel that penetration of the U.S. market will be simpler than generally accepted, and that a 12 month target of $50/share is not unreasonable. Trading today? I don't understand why we're not at $20/share. Margins are currently decent from sales in Europe, and U.S. sales will be through distributors. Most of those revenues should go to the bottom line. I think that, once we clear those sellers who don't understand the company, that we're going up. Just my opinion. Get your own. Cheers! Rick

To: scaram(o)uche who wrote (7185)	4/14/1998 10:11:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 9262

[ VION ] >> they are developing a synthetic melanin for use in cosmetic products. They also have a cancer chemotherapeutic in phase III testing, partnered with Boehringer Ingelheim, and antivirals << It's moving. Plunked on about 15% yesterday and attracting quiet attention today, with bid x ask at 4 5/16 x 4 7/16 with a close yesterday at 4. Bid and ask for GLIA now over 15. Cheers! Rick

To: scaram(o)uche who wrote (7185)	4/27/1998 11:51:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 9262

[ chat Ray, MTRA ] >> Thinking about MTRA and VION << Ray...... post 7185 turned out to be very nicely profitable..... techstocks.com Today's trading (take a look at the intraday, as this all occurred in the last hour)......... MTRA 3 + 5/8 3 1/8 2 1/4 1478 +26.3% Nobody seems interested, but (I think that) every stock that we've highlighted in the past few months has popped, most sooner than MTRA. So, I'm going to keep at it. So, here's the list from Friday's screens. I'll be back to look at tonight's........ Walt1...... John Metcalf's AKRN, that he was recommending last year at about $3. I bought it then, but unfortunately didn't hold it. DITR, etc........ TRGA, TTNP, KDUS. I own TTNP. Big Sto..... UMED and VICL. I'll take a look at tonight's screens and pick a couple. Cheers! Rick